Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease

[1]  E. Loftus,et al.  Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy , 2016, Drug design, development and therapy.

[2]  Jian-Gao Fan,et al.  Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis. , 2015, World journal of gastroenterology.

[3]  C. Roux,et al.  Glucocorticoid-induced osteoporosis , 2015, RMD Open.

[4]  J. Cha,et al.  P568 Adherence to quality measures for inflammatory bowel disease in Korea: Questionnaire study based on American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance Measures Set , 2014 .

[5]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[6]  C. Büning,et al.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease. , 2010, World journal of gastroenterology.

[7]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[8]  G. Porro,et al.  IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. , 2009, Journal of Crohn's & colitis.

[9]  R. Baldassano,et al.  Variation in Care in Pediatric Crohn Disease , 2009, Journal of pediatric gastroenterology and nutrition.

[10]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[11]  H. Raspe,et al.  [Evidence-based and consented pathways for patients with inflammatory bowel diseases (IBD)]. , 2009, Zeitschrift fur Gastroenterologie.

[12]  C. Ricci,et al.  The multidisciplinary team for management of inflammatory bowel diseases. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[14]  S. Targan,et al.  Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes , 2007, Alimentary pharmacology & therapeutics.

[15]  Subrata Ghosh,et al.  Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. , 2007, Journal of Crohn's & colitis.

[16]  M. Vatn,et al.  Relationship between sick leave, unemployment, disability, and health‐related quality of life in patients with inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[17]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[19]  D. Rampton,et al.  Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics , 2006, European journal of gastroenterology & hepatology.

[20]  P. Banks,et al.  Are Patients with Inflammatory Bowel Disease Receiving Optimal Care? , 2005, The American Journal of Gastroenterology.

[21]  D. Felsenberg,et al.  Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  R D Cohen,et al.  The quality of life in patients with Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[23]  P. Rutgeerts,et al.  The limitations of corticosteroid therapy in Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[24]  F. Casellas,et al.  Impact of Inflammatory Bowel Disease on Health-Related Quality of Life , 2000, Digestive Diseases.

[25]  J. Schölmerich,et al.  Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. , 1996, European journal of gastroenterology & hepatology.

[26]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[27]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis. , 1994, Rheumatic diseases clinics of North America.

[28]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[29]  J. Avorn,et al.  Glucocorticoids and the risk for initiation of hypoglycemic therapy. , 1994, Archives of internal medicine.

[30]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[31]  J. Whitworth.  Mechanisms of glucocorticoid-induced hypertension. , 1987, Kidney international.

[32]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[33]  H. Mekhjian,et al.  National Cooperative Crohn's Disease Study: adverse reactions to study drugs. , 1979, Gastroenterology.

[34]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[35]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.